Organic Active Ingredients TRIZ Cases

A composite adhesive layer blends rubber and silicone bases with butorphanol to maintain adhesion stability under warm water or high humidity.

CHP combined with zinc reduces oxidative stress to restore beta-cell function without conventional drug side effects.

Crystal Form A of a tricyclic compound exhibits enhanced stability and reduced hygroscopicity through controlled recrystallization.

Cycloalkyl pyrazolopyrimidine compounds replace toxic ribavirin and expensive monoclonal antibodies with an effective oral treatment.

Novel heterocyclic compound potentiates AMPA receptor function to treat depression and Alzheimer's disease.

Specific sialylated glycans extracted from breast milk prevent bronchitis onset, addressing the lack of effective preventive methods for vulnerable groups.

AAV vectors transport TCAP cDNA to muscle cells, enabling long-term protein expression to treat telethoninopathies like LGMDR7.

A pyrrole derivative acts as a potassium-competitive acid blocker to suppress gastric secretion.

Membrane filtration concentrates ellagitannins from blackberry extracts, eliminating solvent residues and reducing energy costs.

Targeted polyester nanoparticles deliver repair agents to injured brain endothelium, resolving systemic distribution limits.

D-Alanine phosphoramidate pronucleotides enhance bioavailability and efficacy against hepatitis C virus infections.

AM211 DP-2 antagonist blocks PGD2 receptors to stimulate hair growth, addressing unclear mechanisms in androgenetic alopecia treatments.

Analyzing TET1 promoter hypermethylation identifies early-stage cancer risks, resolving the bottleneck of late diagnosis and poor prognosis.

Trioxane thioacetals combine artemisinin with parasiticidal amines to deliver single-dose efficacy, resolving compliance issues from multi-dose regimens.

Quantifying mean interglomerular area differentiates primary from maladaptive FSGS, reducing unnecessary immunosuppressive therapy.

Repeated equal doses of anti-FcεRIα monoclonal antibodies induce rapid allergen desensitization without triggering severe anaphylactic reactions.

High-speed homogenization produces a stable amlodipine dry suspension without surfactants, enabling easier pediatric dosing and industrial scalability.

Formula I compounds inhibit plasmepsin X and IX proteases, blocking parasite egress while reducing drug resistance risks.

NSI-189 treats depression in cognitively impaired patients by matching 80 mg doses to EEG biomarkers, resolving trial-and-error medication selection.